Therma Bright (TSE:THRM) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Therma Bright Inc. has announced its portfolio company InStatin’s new agreement with Mountain West Research to conduct a study aimed at enhancing the delivery of an innovative statin inhalant for asthma and COPD treatment. This research is a significant step towards the development of more effective respiratory therapies and is expected to support upcoming Phase 1 human trials. The company’s investment in InStatin aligns with the growing asthma treatment market, projected to reach USD 39.04 billion by 2032.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue